Compassionate Use of Pozelimab

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT05232110
Status
Approved For Marketing

Conditions

  • CD55-deficient Protein-losing Enteropathy

Eligibility Criteria

Sex
All
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Provide compassionate use of pozelimab

Key Dates

Status verified
Nov 2025